RXYLT1 Gene Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies), Type A10 Genetic Test in UAE

The RXYLT1 gene encodes an enzyme essential for proper glycosylation of alpha-dystroglycan, a protein critical for muscle fiber integrity and brain development. Pathogenic variants in this gene cause muscular dystrophy-dystroglycanopathy type A10, a severe congenital disorder that affects the muscles, brain, and eyes.

This NGS test is ordered when a newborn or infant presents with hypotonia, structural brain malformations such as cobblestone lissencephaly, and ocular anomalies suggestive of Walker-Warburg syndrome. A definitive genetic diagnosis enables accurate prognosis, recurrence risk counselling, and family planning decisions.

Any infant or child presenting with congenital hypotonia, developmental delay, structural brain abnormalities, and ocular defects that raise suspicion of a dystroglycanopathy should undergo RXYLT1 sequencing as a first-tier molecular investigation.

Referring specialists including paediatric neurologists, geneticists, and ophthalmologists may recommend this test. It is also offered for carrier testing in at-risk family members and for prenatal genetic diagnosis when a familial pathogenic variant has been previously identified.

Sample collection is performed via a standard blood draw by our DHA-licensed phlebotomy team during a VIP home visit, available daily from 8 AM to 11 PM. Buccal swabs are also accepted for paediatric patients.

The specimen is transported to our ISO-accredited sequencing laboratory under temperature-controlled cold-chain conditions. Results are reported within 3 to 4 weeks, accompanied by a comprehensive clinical report reviewed and signed by a consultant medical geneticist. Insurance billing verification is available through WhatsApp at +971 54 548 8731.

The report documents all identified variants in the RXYLT1 gene classified according to ACMG/AMP guidelines (pathogenic, likely pathogenic, variant of uncertain significance, likely benign, benign).

It includes an interpretative summary tailored to the patient's phenotype, zygosity assessment, carrier status implications, and recommendations for familial cascade testing and genetic counselling. The report is structured for seamless integration into the referring physician's electronic health record.

Our NGS assay delivers >99.9% analytical sensitivity and specificity for single-nucleotide variants and small indels within the RXYLT1 gene. Limitations include the inability to reliably detect large structural rearrangements, deep intronic variants beyond flanking regions, or variants in non-coding regulatory elements.

If clinical suspicion remains high after a negative result, reflex testing using MLPA or whole-exome sequencing may be considered. All limitations are explicitly stated in the report.